We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cancer Genetics Expands Access to Proprietary Diagnostics Through Agreement with Harvard Pilgrim

By LabMedica International staff writers
Posted on 02 Aug 2015
Print article
Under the terms of a new agreement between Cancer Genetics, Inc. (CGI; Morrisville, NC, USA) and Harvard Pilgrim Healthcare (Hartford, CT; USA), a health care network covering over one million people throughout Massachusetts, Connecticut, and Maine, CGI will offer its cancer diagnostic services to individuals covered under Harvard Pilgrim plans.

Harvard Pilgrim's extensive provider network includes over 135 hospitals and 28,000 clinicians, among them physicians who practice in a variety of settings, including individual practices, small medical groups, and large multi-specialty groups. As part of the agreement, the Harvard Pilgrim’s network will have access to the full range of oncology-focused proprietary tests offered by CGI.

Working with provider networks is central to CGI's multipart access and reimbursement strategy. By establishing relationships with leading payers and insurance companies, CGI plans to expand access to and reimbursement for its leading-edge genomic tests to help providers appropriately manage and personalize treatment.

Cancer Genetics is an emerging leader in DNA-based cancer diagnostics, with tests that target difficult-to-diagnose hematological, urogenital, and HPV-associated cancers, designed to guide prognosis and treatment. Harvard Pilgrim's innovative approach to healthcare and collaboration with top institutions makes it a natural partner for Cancer Genetics.

"Cancer Genetics is very pleased to announce this relationship with Harvard Pilgrim Health Care. HPHC is one of the most respected health plan organizations in New England and is widely regarded for health care innovation, exceptional clinical quality and member satisfaction," said Randy Goodman, PhD, director of Reimbursement and Clinical Revenue Cycle Management, Cancer Genetics, "This agreement not only provides us with the opportunity to deliver services to a larger number of patients, but also allows us to work jointly with HPHC to help transform cancer patient management, increase treatment efficacy and reduce healthcare costs."

Related Links:

Cancer Genetics
Harvard Pilgrim Health Care 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Reagent Reservoirs
Reagent Reservoirs

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.